Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD  by Liesker, Jeroen J.W. et al.
Respiratory Medicine (2011) 105, 1853e1860ava i lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / rmedSputum inflammation predicts exacerbations after
cessation of inhaled corticosteroids in COPD*Jeroen J.W. Liesker a, Erik Bathoorn a, Dirkje S. Postma a, Judith M. Vonk b,
Wim Timens c, Huib A.M. Kerstjens a,*aDepartment of Respiratory Diseases and Tuberculosis, University Medical Center Groningen, University of Groningen,
Hanzeplein 1, P.O Box 30.001, 9700 RB Groningen, The Netherlands
bDepartment of Epidemiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1,
P.O Box 30.001, 9700 RB Groningen, The Netherlands
cDepartment of Pathology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, P.O Box 30.001,
9700 RB Groningen, The Netherlands
Received 10 April 2011; accepted 1 July 2011
Available online 29 July 2011KEYWORDS
Inhaled corticosteroids;
Airway inflammation;
Eosinophil;
Sputum induction;
COPD exacerbation* This study has been registered at h
* Corresponding author. Tel.: þ31 50
E-mail address: h.a.m.kerstjens@l
0954-6111 ª 2011 Elsevier Ltd.
doi:10.1016/j.rmed.2011.07.002
Open aSummary
Introduction: The GOLD guidelines advocate not to institute inhaled corticosteroids (ICS) in
patients with mild-to-moderate COPD. However, many patients do use ICS and in some
patients, withdrawal is associated with deteriorating lung function and increased exacerbation
rates. Unfortunately, physicians do not know in which patients they can stop ICS treatment
safely.
Aim: To identify predictors of COPD exacerbations after ICS withdrawal.
Methods: During ICS treatment, post-bronchodilator spirometry, body plethysmography, and
health status assessment were performed in 68 COPD patients using ICS. Additionally, sputum
cell differentials, supernatant leukotriene B4, eosinophilic cationic protein, and myeloperoxi-
dase, serum C-reactive protein and soluble intracellular adhesion molecule, and urinary des-
mosine were assessed. Sputum was also analysed for mRNA levels of haemoxygenase-1,
tumour necrosis factor-a, RANTES, interleukin 5(IL-5), IL-10, IL-12, IL-13, transforming growth
factor-b, and interferon-g.
Statistics: Cox regression analyses were performed using time to exacerbation as outcome
variable to identify significant hazards for a COPD exacerbation after ICS withdrawal.
Results: Higher sputum % eosinophils, higher sputum MPO/neutrophil level, longer duration of
COPD symptoms, <40 packyears smoking, and ICS withdrawal in November, December or
January were significant hazards (all p< 0.05) for experiencing a COPD exacerbation after
ICS withdrawal in a monovariate model. In a multivariate model, all factors proved indepen-
dent predictors except for sputum MPO/neutrophil level.ttp://www.clinicaltrials.gov, ID: NCT00239278.
3610280; fax: þ31 50 3629320.
ong.umcg.nl (H.A.M. Kerstjens).
ccess under the Elsevier OA license.
1854 J.J.W. Liesker et al.Conclusions: Decisions on whether or not inhaled corticosteroids can be safely withdrawn in
mild-to-moderate COPD can be facilitated by assessment of sputum inflammation, particularly
eosinophil numbers, next to packyears smoking, season, and duration of COPD symptoms.
ª 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Maintenance therapy with inhaled corticosteroids (ICS) in
COPD is extensively debated. Virtually all studies have
shown that ICS reduce exacerbation frequency in certain
patients.1,2 The current guideline of the “Global initiative
for chronic Obstructive Lung Disease” (GOLD) recommends
ICS therapy in COPD patients with a post-bronchodilator
forced expiratory volume in one second (FEV1) <50%pre-
dicted (GOLD stage III/IV) and repeated exacerbations.1 In
contrast to the GOLD-guidelines, many patients with mild-
to-moderate COPD (GOLD stage I/II) also use ICS on a daily
basis.3 Additionally, there is reluctance to take patients off
ICS who are already using them, which is likely linked to the
experience that exacerbations occur frequently after stop-
ping corticosteroids. This clinical notion of the difficulty to
stop ICS in a substantial subgroup of COPD patients is now
supported by at least two randomized trials investigating the
effects of ICS withdrawal.4,5
The long-term use of ICS is associated with adverse
effects and marked costs. If indeed some patients can do
well without continuing their inhaled corticosteroid use,
while others will do worse, it would be of great value to be
able to estimate an individual’s future exacerbation risk
after stopping ICS. To our knowledge, no study so far has
investigated the role of inflammatory parameters as a risk
factor for an ensuing exacerbation after ICS withdrawal,
though Siva et al have shown that COPD patients with
sputum eosinophilia could reduce exacerbation frequency
by inhaled steroids.6 Therefore, we expected that espe-
cially higher sputum eosinophil percentages are a hazard
for clinical deterioration.
To address the issue of prediction of exacerbations after
ICS withdrawal we performed a study in which we dis-
continued ICS and searched for predictors of early exacer-
bations. Airway inflammation, patient characteristics, lung
function, and health status were assessed in stable COPD
patients before ICS withdrawal. After ICS withdrawal, time
to exacerbation was assessed. We hypothesized that COPD
patients with more active airway inflammation before ICS
withdrawal are at increased risk for exacerbations.
Methods
Subjects
Smokers and ex-smokers with a diagnosis of COPD were
included if on inhaled corticosteroid maintenance therapy,
aged above 40 years, with a post-bronchodilator FEV1 below
85% of predicted but above 0.7 l, and with a post-
bronchodilator FEV1/inspiratory vital capacity (IVC) below
predicted (<88% predicted in men and <89% predicted in
women). Patients with a history of asthma, using long-termoxygen therapy, or with significant other disease that could
influence the results of the study were excluded. The use of
oral corticosteroids was not allowed from 4 weeks before
inclusion. The local medical ethics committee approved the
study. A written informed consent was obtained from all
patients prior to the study.
Study design
This manuscript presents the analysis of the period from
study enrolment to the time of the first exacerbation. When
patients exacerbated, a randomized controlled trial was
conducted which is reported separately.7
At the enrolment visit, medical history was taken and
a physical examination was performed. In addition spirom-
etry andbodyplethysmographywereperformed, followedby
sputum induction, quality of life questionnaires, blood, and
urine sampling. At the end of this visit ICS were discontinued
and the time to exacerbation was monitored. Because of the
above mentioned ensuing randomized controlled trial, long-
acting b2-agonist were changed to short-acting b2-agonists
two months after enrolment. Patients were instructed to
contact the investigators when pulmonary symptoms
occurred or deteriorated. An exacerbation was defined
according to the definition of Davies et al., i.e. increased
breathlessness and at least twoof the following symptoms for
24 h or more: increased cough frequency or severity,
increased sputum volume or purulence, and increased
wheeze,8 requiring extra prednisolone and/or antibiotics
after ICS discontinuation as judged by a medical doctor.
Measurements
At the enrolment visit, post-bronchodilator spirometry and
bodyplethysmography (Jaeger Pneumotachograph/Master-
screen body, VIASYS Healthcare Inc, Conshohocken, USA)
were performed after inhalation of 400 mg salbutamol
according to ERS standards.9 Directly after the lung function
measurements, a sputum induction was performed with
nebulised 4.5% sodium chloride solution for 3 5 min, with
modifications when FEV1 was below 1.5 l.
10 Subsequently
blood and urine samples were collected. Finally, health
statuswas assessed by the Chronic RespiratoryQuestionnaire
(CRQ),11 and the Clinical COPD Questionnaire (CCQ).12
Higher scores in the CRQ represent better health status,
while higher scores in the CCQ representworse health status.
Sputum processing
The whole sputum sample was processed. Differential cell
counts were performed and soluble mediators were
measured in sputum supernatant by ELISA: leukotriene-B4
(LTB4), eosinophilic cationic protein (ECP), and myeloper-
oxidase (MPO) (see online supplement).
Table 1 Baseline clinical anddemographic characteristics.
Number of patients 68
Number of exacerbations 54
Gender (m/f) 53/15
Median 25e75 percentile
Age (years) 64.2 58.6e70.6
Packyears smoking 40.0 28.5e51.8
BMI (kg m2) 26.3 23.9e28.6
Daily dose of ICS (mg) 800 500e1000
Post-bronchodilator lung function
FEV1 (L) 1.84 1.41e2.24
FEV1 (%pred) 63.0 50.7e75.4
FVC (%pred) 100.0 90.5e106.0
IVC (%pred) 104.2 93.4e115.5
FEV1/IVC 0.47 0.38e0.55
sGAW (kPa s)1 0.67 0.45e1.02
TLC (L) 7.63 6.71e8.38
TLC (%pred) 114.7 105.8e126.9
ITGV (%pred) 133.8 116.2e151.5
RV (%pred) 146.8 125.4e164.4
ITGV%TLC (%pred) 108.7 101.5e115.1
RV%TLC (%pred) 116.3 104.2e128.5
Health status-Chronic Respiratory Questionnaire
Total score 19.4 17.4e21.6
Health status-COPD
Control Questionnaire
Total score 2.00 1.40e2.58
All variables are expressed as median, interquartile range. BMI,
body mass index; ICS, inhaled corticosteroids; FEV1, forced
expiratory volume in one second; FVC, forced vital capacity;
IVC, inspiratory vital capacity; sGAW, specific airway conduc-
tance; TLC, total lung capacity; ITGV, intra-thoracic gas
volume; RV, residual volume; IC, inspiratory capacity.
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For more details, see online supplement. In short,
messenger ribonucleic acid (mRNA) was harvested from 1x
106 non-squamous sputum cells. Expression of cytokine
mRNA was analysed for haemoxygenase-1 (HO-1), tumour
necrosis factor alpha (TNF-a), regulated on activation,
normal T-cell expressed and secreted (RANTES), interleukin
5 (IL-5), IL-10, IL-12, IL-13, transforming growth factor-
b (TGF-b), interferon-g (IFN-g), and b2-microglobulin were
analysed by quantitative real-time PCR (see online
supplement). Cytokine gene expression was normalised to
b2-microglobulin expression. The mRNA quantification is
expressed in threshold cycle (Ct) values, which is the
number of amplification cycles to reach a detectable mRNA
amount. Thus lower Ct-values correspond with higher mRNA
expression. These values were available for 46 subjects,
because it was added to the protocol later.
Blood and urine analyses
Methods for determination of blood differential cell counts,
C-reactive protein (CRP), soluble intercellular adhesion
molecule (sICAM), and urine desmosine are presented in the
online supplement.
Statistics
Baseline characteristics are presented as medians (inter-
quartile range). Continuous variables were tested for line-
arity with time-to-exacerbation. Non-linearly related
variables were logarithmitised, tested again, and otherwise
dichotomised using the median values as cut-off. Mono-
variate Cox regression analyses were performed using
patient characteristics, lung function, sputum, urine,
blood, and health status parameters to identify significant
hazards of experiencing a COPD exacerbation after ICS
discontinuation. The survival variable used was “time to
exacerbation”, defined as the time to the first exacerba-
tion. The survival variable was censored, that is, it contains
survival times and patients not experiencing an exacerba-
tion before the end of the study. Multivariate Cox regres-
sion analysis was used to adjust survival comparisons for
potential confounders, using the factors with a p-value
<0.10 from the monovariate analyses. KaplaneMeier curves
were used to compare survival in subpopulations defined by
medians of a single variable. Correction for the effect of
seasonality on exacerbation prediction was done after
inspecting plots, by defining a dichotomous variable indi-
cating withdrawal in November, December or January, as
opposed to outside those three months. A p-value <0.05
was considered to be significant.
Results
Baseline characteristics
Sixty-eight of the 114 screened patients with COPD were
included between January 2001 and January 2005. The
main reasons for exclusion were failure to meet theinclusion criteria (not-using ICS, cardiovascular instability,
and lung function criteria) and inability to produce an
adequate sputum sample at visit 1. The 68 included
patients were monitored for a median (interquartile range)
time of 146 (75e357) days. Fifty-four patients experienced
an exacerbation, after a median time of 132 (70e214) days.
The baseline characteristics of the patients included in the
current analyses are presented in Table 1, and their
inflammatory parameters in Table 2.Monovariate Cox regression analyses
Baseline characteristics
Duration of COPD symptoms (duration of COPD) was
a significant demographic risk factor for developing a COPD
exacerbation after ICS withdrawal (Hazard ratio (HR) 1.07,
pZ 0.001, Table 3). Season of ICS withdrawal (November,
December, or January) also proved to be a hazard (HR 4.2,
p< 0.001). Packyears was dichotomised using the median
value (40). Having smoked <40 packyears was a predictor
for developing an exacerbation (HR 0.54, pZ 0.03). None
of the other baseline values such as age, gender, current
smoking, body mass index, daily dose of ICS, and blood
Table 2 Baseline inflammatory characteristics.
Median 25e75
percentile
Sputum cells
Total cell count ( 106//ml) 5.37 2.26e13.5
Viability (%) 85.3 77.6e92.4
Eosinophilsa (%) 1.60 0.50e3.73
Neutrophils (%) 72.7 62.3e81.5
Macrophages (%) 18.6 13.4e29.7
Lymphocytes (%) 0.70 0.20e1.50
Sputum supernatant proteins
ECP (mg/l) 151 56e420
ECP/eosinophils (mg/109 cells) 1423 583e3276
MPO (mg/ml) 12.3 6.57e40.8
MPO/neutrophils(mg/106 cells) 3.70 1.67e8.17
LTB4 (ng/ml) 0.49 0.28e1.17
Sputum mRNA. Ct-values. NZ 47
RANTES 28.9 28.4e29.6
IL-5 41.1 37.3e42.9
IL-10 29.8 29.2e30.5
IL-12a 41.9 38.1e42.9
IL-12b 41.0 37.0e42.8
IL-13 41.0 36.5e42.6
IFN-g 34.2 32.9e35.1
TGF-b 25.7 24.7e26.2
TNF-a 26.5 26.1e27.4
Haemoxygenase-1 25.5 25.1e26.1
Serum
CRP (mg/l) 3.36 1.85e7.51
sICAM (ng/ml) 115.3 95.4e155.8
Urine
Desmosine (mM/mmol
creatinine/l)
15.7 8.90e25.3
All variables are expressed as median, interquartile range. ECP:
eosinophilic cationic protein; MPO, myeloperoxidase; LTB4,
leukotriene-B4; CRP, C-reactive protein; sICAM, soluble inter-
cellular adhesion molecule; RANTES, regulated on activation;
normal T-cell expressed and secreted; IL, interleukin; IFN-g,
interferon-gamma; TNF-a, tumour necrosis factor-alpha; TGF-b,
transforming growth factor-beta; Ct-values, cycle threshold
values, which is the number of amplification cycles to reach
detectable mRNA amount, normalised for b2-microglobulin
expression. Lower Ct-values correspond with higher mRNA
expression.
a Sputum eosinophils were <3% in 47 out of 68 subjects.
Table 3 Significant monovariate Cox regression hazard
ratios for time to exacerbation.
Hazard
ratio
95% CI p-Value
Packyears smoking  40b 0.54 0.31e0.93 0.03
Durations of symptoms
(years)
1.07 1.03e1.11 0.001
ICS cessation in
November, December
or Januaryc
4.16 2.02e8.57 <0.001
% sputum eosinophilsa 1.42 1.10e1.83 0.007
Serum MPO (mg/106
neutrophils)a
1.36 1.08e1.71 0.01
Serum CRP (mg/l)a 0.79 0.61e1.02 0.065
a Logarithmitised.
b Dichotomised using the median value at baseline.
c Dichotomised as “in” versus “outside” the period.
Figure 1 Kaplan-Meier plot of risk of exacerbation in
subjects with 3.0% sputum eosinophils (solid line) and
subjects with <3.0% sputum eosinophils before ICS withdrawal
(dotted line) (pZ 0.005).
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Cox regression analyses. Similarly, health related quality of
life as determined by CRQ or CCQ was not predictive of
time to exacerbations. For a table with all characteristics
tested, see online Supplementary Table E1.
Lung function
None of the lung function parameters reflecting airway
obstruction (FEV1, FVC, FEV1/FVC, sGAW) or hyperinflation
(TLC, RV, FRC, FRC%TLC, ITGV%TLC) were statistically
significant risk factors of the time to exacerbation in
a monovariate model. When the severity of airwayobstruction was categorised by GOLD stage, this too
was not predictive of an exacerbation (Supplementary
Table E1).
Inflammation
Sputum eosinophil percentage was a significant hazard for
developing an early COPD exacerbation (HR 1.42,
pZ 0.007, Table 3). In a prior study, ICS treatment showed
to be most beneficial in COPD patients with a baseline
sputum eosinophil count above 3%.6 Therefore, % sputum
eosinophils were also tested as a dichotomous variable
(3% versus <3%) in the survival analysis. Subjects with
more than 3% sputum eosinophils had a significantly
increased risk for earlier development of an exacerbation
compared to subjects with lower percentages of sputum
eosinophils (Fig. 1). Neutrophils, macrophages, and
lymphocytes were not predictive of an exacerbation,
neither expressed as cell numbers nor as % of total sputum
Sputum eosinophilia predicts COPD exacerbations 1857cell count. Sputum MPO level per neutrophil was a signifi-
cant hazard for experiencing an exacerbation (see Table 3),
but not sputum MPO level per se, nor sputum ECP level, ECP
per eosinophil, and LTB4. The hazard ratio of serum CRP
was 0.79, and just failed to be significant (pZ 0.065). The
hazard ratios of mRNA-levels for RANTES, IL-5, IL-10, IL-
12a, IL-12b, IL-13, TGF-b, TNF-a, and IFN-g did not reach
statistical significance, nor did the hazard ratios of soluble
ICAM levels, and urinary desmosine (corrected for creati-
nine) (Supplementary Table E1).
Multivariate analyses
All factors with a p-value below 0.10 in the monovariate
analyses were included in a multivariate model (see Table
3). Percentage sputum eosinophils, longer duration of
COPD symptoms, less than 40 pack years smoking, and
season of inclusion proved to be independent predictors for
experiencing a COPD exacerbation after ICS withdrawal
(Table 4). Using the variable 3% sputum eosinophils
instead of % sputum eosinophils did not change the results.
Discussion
This study shows that sputum eosinophilia, the duration of
COPD symptoms and smoking habits, and season are
predictive for an earlier exacerbation in patients with mild-
to-moderate stable COPD when indiscriminately taken off
their inhaled corticosteroids.
According to the GOLD guidelines, many patients who are
currently treated with ICS should in fact not be using them.
Thus doctors should withdraw ICS from these patients.
However, in practice, this poses marked problems in some
patients. Predictors to assess the patient’s exacerbation risk
would be helpful for clinicians to aid in deciding whether or
not to discontinue ICS therapy. Although many patient
characteristics have been identified that are associated with
an increased risk of developing a COPD exacerbation13e27 to
our knowledge no study has been published in which
inflammatory parameters were evaluated as risks for exac-
erbation after ICS discontinuation.Table 4 Multivariate Cox regression hazard ratios for time
to exacerbation.
Hazard
ratio
95% CI p-Value
Packyears smoking  40b 0.57 0.32e1.00 0.05
Durations of symptoms
(years)
1.06 1.02e1.10 0.003
ICS cessation in
November, December
or Januaryc
3.61 1.67e7.79 0.001
% sputum eosinophilsa 1.34 1.04e1.71 0.02
Serum MPO (mg/106
neutrophils)a
1.18 0.90e1.53 0.23
Serum CRP (mg/l)a 0.79 0.58e1.07 0.12
a Logarithmitised.
b Dichotomised using the median value at baseline.
c Dichotomised as “in” versus “outside” the period.In our study, percentage of sputum eosinophils, assessed
in a stable phase of the disease while patients were still
using ICS therapy, was a significant predictor for develop-
ment of an earlier COPD exacerbation after ICS discontin-
uation. It has been suggested previously that the numbers
of eosinophils28e31 and their chemo-attractants32,33 are
increased during COPD exacerbations. Sputum eosinophilia
can be present in stable disease and more importantly, we
now demonstrate that increased eosinophil percentages
predict a shorter time to exacerbation after discontinua-
tion of ICS. Additionally, previous studies have shown that
especially COPD patients with an eosinophilic inflammatory
pattern in their sputum benefit most from ICS maintenance
therapy32 and from oral corticosteroids during stable
COPD.34 This is in line with the fact that the eosinophil is
a very steroid-sensitive cell type.
Siva et al. have recently reported a study in which
steroid maintenance treatment based on sputum eosinophil
levels resulted in a decrease in severe exacerbation rates.6
Our finding that patients with higher percentage of sputum
eosinophils (before ICS withdrawal) are at an increased risk
for developing a COPD exacerbation after ICS withdrawal is
fully compatible with their study. From their study and our
findings, we conclude that it might be problematic to
withdraw ICS in patients with higher eosinophil levels for
trial purposes, and less desirable in the clinical setting. Our
data suggest that a decision to discontinue the ICS should
be made on the sputum eosinophil percentage. Subjects
with more than 3.0% eosinophils should probably not dis-
continue their ICS because their chance of experiencing an
exacerbation is markedly higher. It would now be timely to
perform a prospective study in patients with COPD in whom
discontinuation of inhaled corticosteroids is considered
dependent on the sputum eosinophil percentage.
COPD has traditionally been regarded as disease with
a major neutrophilic component. Neutrophil numbers were
not a significant risk factor for earlier COPD exacerbation
after ICS discontinuation. Since corticosteroids are less
effective in reversing neutrophilia than eosinophilia,34 we
did not expect that the presence of higher numbers of
neutrophils would constitute a high risk for exacerbations
specifically after ICS withdrawal. Sputum neutrophil
numbers could have proven, however, to be predictive of
increased exacerbation risk independent of ICS withdrawal,
but this was not the case in our study. Monovariate Cox
proportional hazard survival analysis showed that neutro-
phil activation as assessed by the level of MPO/neutrophil
in sputum was related to the development of an exacer-
bation, but the significance was lost in the multivariate
model. One of the main functions of MPO is its anti-
bacterial effect. MPO levels are highly correlated with
bacterial load in bronchoalveolar lavage in a combined
group of patients with stable obstructive and non-
obstructive chronic bronchitis.35 Furthermore, MPO levels
are significantly higher in patients with higher bacterial
load in their sputum during an exacerbation.36 Thus, it is
possible that the activation level of neutrophils in our
patients reflects bacterial colonisation of the airways more
than a trait amenable to steroid effects.
Low serum CRP levels tended to be a risk factor for
development of a COPD exacerbation after ICS withdrawal
in the monovariate model. Former studies in COPD showed
1858 J.J.W. Liesker et al.that oral and inhaled corticosteroids reduce37 and ICS
withdrawal raises CRP levels.38 We postulate that low CRP
levels may reflect effective control of airway inflammation
in COPD patients on ICS, and that ICS withdrawal leads
more easily to an exacerbation especially in these patients.
Sputum cytokine mRNA levels (IL-5, IL-10, IL-12aþb, IL-
13, TNF-a, TGF-b, and IFN-g) did not identify persons at risk
for developing a COPD exacerbation after ICS withdrawal in
our sub-study of 46 patients with mRNA determinations. We
can not rule out that the use of inhaled corticosteroids by
our subjects might have contributed to this. Alternatively,
this may also imply that mRNA is not an optimal way to
assess the potential of measuring cytokines and mediators
in a pending exacerbation after ICS withdrawal, or that our
number of patients was too low to address this issue, or
that there were technical issues not yet indentified by us.
Further studies clearly have to replicate this, as well as
extend our observations to the protein level.
Perhaps the most remarkable finding is that the level of
FEV1 was not predictive of the time to exacerbation in
patients with mild-to-moderate COPD. In the much larger,
recently published data from the Eclipse study 25, a lower
FEV1 was associated with a higher risk of being a frequent
exacerbator, but there were marked numbers of patients
with frequent exacerbators also in patients with an FEV1
between 50 and 80% predicted (GOLD 2). The emphasis in
the current guidelines1 to only prescribe ICS to patients
with an FEV1 below 50% predicted in combination with an
increased exacerbation frequency should be re-evaluated.1
It remains, however, totally logic not to prescribe ICS to
reduce the number of exacerbations in patients who do not
experience any exacerbation, but uncoupled from GOLD
stage. Indeed the study in the literature (Jones et al.) on
which this criterion of only prescribing ICS to patients with
an FEV1 was based,
39 found a larger absolute reduction in
exacerbation frequency in patients with an FEV1 above 50%
predicted than below 50%. However, the reduction in
exacerbation frequency was only significant in the group of
patients with an FEV1 below 50% predicted.
Time since onset of COPD symptoms was also a signifi-
cant predictor of increased risk of exacerbations when ICS
were discontinued. This duration of COPD was predictive
for exacerbations and hospitalizations in one previous
larger study.14 Unfortunately, we do not have data on prior
exacerbation frequency, which in the Eclipse study proved
to be the best predictor of future exacerbation
frequency.25 None of the other baseline characteristics,
lung function or health status parameters, turned out to be
significant predictors in our study. Numerous other non-
inflammatory risk factors for (hospitalization due to)
exacerbations have been found in previous studies.13e20
These observational studies were usually in larger cohorts
of hospitalised patients. We are aware that our study may
have included a too small number of patients to find some
of the above-mentioned hazards for exacerbations.
However, our significant result with eosinophils was already
apparent in a study with only a low sample size and may
underline the importance of sputum inflammation.
Opposite to what we had expected, smoking more than
40 packyears was a protective factor for developing a COPD
exacerbation after ICS withdrawal. We speculate that
a healthy smoker effect is responsible for this finding,which means that patients who do not tend to exacerbate
can keep on smoking and that withdrawal of ICS does not
change this tendency.
Themultivariatemodelwas corrected for seasonal effects
by including a factor on whether ICS withdrawal occurred in
November, December, or January. This season had a signifi-
cant hazard ratio of 3:5. This seasonal effect was expected
because periods with high frequency of COPD exacerbations
parallels periods with high incidence of respiratory viruses.40
After correction of the seasonal influence, % sputum eosin-
ophils, duration of COPD symptoms, and packyears smoking
remained independent predictors of time to exacerbation in
the multivariate model. Although perhaps not unexpected,
we believe this is the first study to document that discon-
tinuation of ICS in November, December, or January poses
increased risks of exacerbations.
We conclude that assessment of sputum inflammation
can aid the physician to decide which COPD patient using
ICS can actually stop this treatment outside the exacerba-
tion season without increased risk of an early exacerbation.
Sputum eosinophilia is the most informative inflammatory
parameter in this respect, and to a smaller extent neutro-
phil activation. Independent other predictors were pack-
years smoking and duration of symptoms. We suggest that
the evaluation of sputum eosinophilia greater than 3% can
be employed prospectively for a treatment decision with
respect to discontinuation of inhaled corticosteroids in
patients with mild-to-moderate COPD.
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